William J Catalona

NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023

Journal of the National Comprehensive Cancer Network · 2023 · 148 citations

The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for individuals with a prostate who opt to participate in an early detection program after receiving the appropriate counseling on the pros and cons. These NCCN Guidelines Insights provide a summary of recent updates to the NCCN Guidelines with regard to the testing protocol, use of multiparametric MRI, and management of negative biopsy results to optimize the detection of clinically significant prostate cancer and m…

Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer

JAMA Oncology · 2023-09-21 · 51 citations

Importance: Germline gene panel testing is recommended for men with advanced prostate cancer (PCa) or a family history of cancer. While evidence is limited for some genes currently included in panel testing, gene panels are also likely to be incomplete and missing genes that influence PCa risk and aggressive disease. Objective: To identify genes associated with aggressive PCa. Design, Setting, and Participants: A 2-stage exome sequencing case-only genetic association study was conducted includin…

Polygenic Risk Score and Upgrading in Patients With Prostate Cancer Receiving Active Surveillance

JAMA Oncology · 2024-12-12 · 14 citations

Importance: Active surveillance is the preferred management strategy for patients with low- or favorable intermediate-risk prostate cancer (PCa); however, frequent health care visits can be costly and burdensome to patients. Identifying patients who may benefit from intensive vs passive surveillance could reduce these burdens. Objective: To investigate associations between a polygenic risk score (PRS) and risk of upgrading and other prostate tumor features in patients receiving active surveillan…

Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020

JAMA · 2024-11-20 · 12 citations

This cross-sectional study evaluates trends and factors associated with selecting active surveillance or watchful waiting among individuals with intermediate-risk prostate cancer.

Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer

BJUI Compass · 2023-08-15 · 6 citations

Background: Tissue-based gene expression (genomic) tests provide estimates of prostate cancer aggressiveness and are increasingly used for patients considering or engaged in active surveillance. However, little is known about patient experiences with genomic testing and its role in their decision-making. Methods: We performed a qualitative study consisting of in-depth, semi-structured interviews of patients with low- or favourable-intermediate-risk prostate cancer managed with active surveillanc…